Showing results (51-60 of 83) with videos related to
Sort By:
Pageof 9
Diabetes, Obesity & Metabolism|April 25, 2020
Days absent from work as a result of complications associated with type 2 diabetes: Evidence from 20 years of linked national registry data in SwedenSofie Persson, Pierre Johansen, Emelie Andersson, et al.Journal of the American Society of Hypertension : JASH|March 18, 2018
Effects on repetitive 24-hour ambulatory blood pressure in subjects with type II diabetes randomized to liraglutide or glimepiride treatment both in combination with metformin: a randomized open parallel-group studyJohan Jendle, Xin Fang, Yang Cao, et al.Frontiers in Endocrinology|November 30, 2017
Effects on Subclinical Heart Failure in Type 2 Diabetic Subjects on Liraglutide Treatment vs. Glimepiride Both in Combination with Metformin: A Randomized Open Parallel-Group StudyThomas Nyström, Irene Santos-Pardo, Fredric Hedberg, et al.Frontiers in Endocrinology|March 2, 2018
Corrigendum: Effects on Subclinical Heart Failure in Type 2 Diabetic Subjects on Liraglutide Treatment vs. Glimepiride Both in Combination with Metformin: A Randomized Open Parallel-Group StudyThomas Nyström, Irene Santos-Pardo, Fredric Hedberg, et al.Scientific Reports|March 31, 2026
Effects of automated insulin delivery systems on glucose control in subgroups of adults with type 1 diabetes in clinical practice over 2 years in SwedenRamanjit Singh, Henrik Imberg, Shilan Seyed Ahmadi, et al.Diabetes, Obesity & Metabolism|May 7, 2021
Real-world performance of the MiniMed™ 670G system in EuropeJulien Da Silva, Emanuele Bosi, Johan Jendle, et al.Journal of Diabetes Science and Technology|April 17, 2024
Effects, Safety, and Treatment Experience of Advanced Hybrid Closed-Loop Systems in Clinical Practice Among Adults Living With Type 1 DiabetesRamanjit Singh, Henrik Imberg, Shilan Seyed Ahmadi, et al.Diabetes Technology & Therapeutics|October 6, 2023
A European Cost-Utility Analysis of the MiniMed™ 780G Advanced Hybrid Closed-Loop System Versus Intermittently Scanned Continuous Glucose Monitoring with Multiple Daily Insulin Injections in People Living with Type 1 DiabetesJohan Jendle, Maria Ida Buompensiere, Asli Zeynep Ozdemir Saltik, et al.The Journal of Clinical Endocrinology and Metabolism|August 10, 2019
Switching to Degludec From Other Basal Insulins Is Associated With Reduced Hypoglycemia Rates: A Prospective StudyGian Paolo Fadini, Michael Feher, Troels Krarup Hansen, et al.Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|July 16, 2020
Switching to Degludec is Associated with Reduced Hypoglycaemia, Irrespective of Definition Used or Patient Characteristics: Secondary Analysis of the ReFLeCT Prospective, Observational StudyHarold W de Valk, Michael Feher, Troels Krarup Hansen, et al.Pageof 9